A drug used to
treat advanced renal cell carcinoma (the most common type
of kidney cancer). It is used in patients who have not
gotten better with other anticancer drugs. It is also being
studied in the treatment of other types of cancer.
Inlyta blocks the action of
proteins called growth factor receptors and may prevent the
growth of new blood vessels that tumors need to grow. It is
a type of tyrosine kinase inhibitor and a type of
antiangiogenesis agent. Also called axitinib.